Literature DB >> 25228006

Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment.

M Tong1, C A Viall2, L W Chamley2.   

Abstract

BACKGROUND: Antiphospholipid antibodies (aPL) are a family of auto-antibodies that are associated with an increased risk of recurrent miscarriage, intrauterine growth restriction and preterm birth. The placenta is a major target of aPL and it is likely that these antibodies promote pregnancy morbidity by affecting trophoblast function. Numerous studies have investigated the effect of aPL on trophoblast function in vitro. However, different trophoblast models and a variety of culture conditions have been employed, resulting in a myriad of different reported findings. This review systematically summarized those published studies that have investigated the effect of aPL on trophoblast function in vitro. In addition, the reported effects of pharmacological treatment on trophoblast function in the presence of aPL were also systematically reviewed.
METHODS: PubMed, Scopus, Embase and Web of Science databases were searched using the keywords 'placenta OR trophoblast' AND 'antiphospholipid antibody OR antiphospholipid syndrome' up to 25 April 2014. Studies were excluded based on the absence of appropriate controls. The effects of aPL on trophoblast proliferation, death, syncytialization, invasion, hormone production, cytokine production, coagulation and complement activation were recorded. The effects of different treatments on the function of trophoblasts in the presence of aPL were also recorded.
RESULTS: A total of 1071 records were retrieved from the four databases. After removing duplicates, the titles and abstracts of 529 articles were reviewed. Of those, 48 articles were read and relevant experimental results were extracted from 47 articles.
CONCLUSIONS: This systematic review provides an overview of all the studies performed to date on the effects of aPL on trophoblast function in vitro. There is considerable support for aPL decreasing trophoblast viability, syncytialization and invasion in vitro. Some work has also suggested that aPL may affect the production of hormones and signalling molecules by trophoblasts, and may stimulate coagulation and complement activation in vitro. Current reports of the in vitro effects of therapeutic treatments on trophoblast function in the presence of aPL are inconclusive. This systematic review has highlighted many gaps in our knowledge of how aPL work and may direct future research in this area.
© The Author 2014. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  antiphospholipid antibody; antiphospholipid antibody syndrome; placenta; pregnancy; trophoblast

Mesh:

Substances:

Year:  2014        PMID: 25228006     DOI: 10.1093/humupd/dmu049

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  20 in total

1.  ApoE Receptor 2 Mediation of Trophoblast Dysfunction and Pregnancy Complications Induced by Antiphospholipid Antibodies in Mice.

Authors:  Jane E Salmon; Chieko Mineo; Victoria Ulrich; Shari E Gelber; Milena Vukelic; Anastasia Sacharidou; Joachim Herz; Rolf T Urbanus; Philip G de Groot; David R Natale; Anirudha Harihara; Patricia Redecha; Vikki M Abrahams; Philip W Shaul
Journal:  Arthritis Rheumatol       Date:  2016-03       Impact factor: 10.995

2.  Enhancement of trophoblast differentiation and survival by low molecular weight heparin requires heparin-binding EGF-like growth factor.

Authors:  Alan D Bolnick; Jay M Bolnick; Hamid-Reza Kohan-Ghadr; Brian A Kilburn; Omar J Pasalodos; Pankaj K Singhal; Jing Dai; Michael P Diamond; D Randall Armant; Sascha Drewlo
Journal:  Hum Reprod       Date:  2017-06-01       Impact factor: 6.918

Review 3.  Interferons and Proinflammatory Cytokines in Pregnancy and Fetal Development.

Authors:  Laura J Yockey; Akiko Iwasaki
Journal:  Immunity       Date:  2018-09-18       Impact factor: 31.745

4.  Low molecular weight heparin and aspirin exacerbate human endometrial endothelial cell responses to antiphospholipid antibodies.

Authors:  Zola Chihombori Quao; Mancy Tong; Elena Bryce; Seth Guller; Lawrence W Chamley; Vikki M Abrahams
Journal:  Am J Reprod Immunol       Date:  2017-11-14       Impact factor: 3.886

5.  Immunological parameters of recurrent miscarriages among women in Thi-Qar province.

Authors:  Ghaneemah Malik Hamadi; Sally Fadhel Lafta
Journal:  J Med Life       Date:  2022-05

Review 6.  Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review.

Authors:  Amelia Ruffatti; Ariela Hoxha; Maria Favaro; Marta Tonello; Anna Colpo; Umberto Cucchini; Alessandra Banzato; Vittorio Pengo
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

7.  Antiphospholipid Antibodies Inhibit Trophoblast Toll-Like Receptor and Inflammasome Negative Regulators.

Authors:  Melissa J Mulla; Ingrid C Weel; Julie A Potter; Stefan M Gysler; Jane E Salmon; Maria T S Peraçoli; Carla V Rothlin; Lawrence W Chamley; Vikki M Abrahams
Journal:  Arthritis Rheumatol       Date:  2018-04-25       Impact factor: 10.995

8.  Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome.

Authors:  Maria Laura Bertolaccini; Gregorio Contento; Ross Lennen; Giovanni Sanna; Philip J Blower; Michelle T Ma; Kavitha Sunassee; Guillermina Girardi
Journal:  J Autoimmun       Date:  2016-05-06       Impact factor: 7.094

Review 9.  New Insights in the Pathophysiology of Antiphospholipid Syndrome.

Authors:  Anastasia Sacharidou; Philip W Shaul; Chieko Mineo
Journal:  Semin Thromb Hemost       Date:  2017-01-27       Impact factor: 6.398

Review 10.  Effects of anti-beta 2-glycoprotein 1 antibodies and its association with pregnancy-related morbidity in antiphospholipid syndrome.

Authors:  Juan J Fierro; Manuela Velásquez; Angela P Cadavid; Karina de Leeuw
Journal:  Am J Reprod Immunol       Date:  2021-12-04       Impact factor: 3.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.